Difficulty swallowing
Food sticking or pain on swallowing — the cardinal oesophageal symptom.
Gastrointestinal cancer is a broad category covering the oesophagus, stomach, small intestine, gallbladder and pancreas. Each behaves differently — but all benefit from multidisciplinary planning, where AARO contributes chemoradiation expertise and pioneering pancreas SBRT experience.
Gastrointestinal cancers arise from uncontrolled cell growth in any organ of the digestive system, and are categorised by organ and cell type. Oesophageal cancers are mostly squamous cell carcinomas (upper and middle oesophagus) or adenocarcinomas (lower oesophagus). Stomach cancers are 90–95% adenocarcinomas, though lymphomas, gastrointestinal stromal tumours (GISTs) and carcinoid tumours also occur.
Small intestine cancers most often begin in the duodenum and include adenocarcinomas, slow-growing carcinoid tumours, lymphomas and sarcomas. Gallbladder cancers are rare and nearly all adenocarcinomas.
Pancreatic cancers mostly arise from the exocrine glands — ductal adenocarcinoma being the most common — with less common neuroendocrine tumours arising from the hormone-producing cells. Because each of these diseases behaves so differently, the exact diagnosis drives everything that follows.
GI cancers often develop quietly — pre-cancerous changes in the stomach, for instance, rarely cause symptoms. See a doctor promptly for:
Food sticking or pain on swallowing — the cardinal oesophageal symptom.
Ongoing indigestion, bloating or upper abdominal discomfort, especially if new after 50.
Losing weight without trying accompanies many GI cancers.
Black stools or blood in vomit signal bleeding that needs urgent assessment.
Yellowing of skin and eyes — a key sign in pancreatic and gallbladder disease.
Both can be presenting features of pancreatic cancer.
Endoscopy and modern imaging reach every part of the digestive tract — establishing the exact site, type and stage.
Gastroscopy visualises the oesophagus, stomach and duodenum directly; suspicious areas are biopsied at the same sitting.
Pathology confirms the cancer type — adenocarcinoma, GIST, lymphoma or neuroendocrine — which changes the treatment entirely.
Cross-sectional imaging and endoscopic ultrasound define the tumour's depth, local invasion and nodal involvement.
Whole-body imaging completes the stage and shapes whether treatment aims at cure or control.
Risk factors vary by organ — but several recur across the digestive tract:
Both raise risk across oesophageal, stomach and pancreatic cancers.
Chronic Helicobacter pylori infection is a major stomach cancer risk factor — and it's treatable.
Long-standing reflux can transform the lower oesophageal lining, raising adenocarcinoma risk.
Diets high in salted, smoked and preserved foods raise stomach cancer risk.
Both are associated with oesophageal, pancreatic and gallbladder cancers.
Inherited syndromes and family history raise risk for several GI cancers.
GI cancers are treated by multidisciplinary teams — surgery, radiation and systemic therapy sequenced deliberately. AARO's contribution centres on precision radiation where it demonstrably changes outcomes.
Pre-operative chemoradiation for oesophageal and selected stomach cancers shrinks tumours and improves surgical outcomes.
Ablative stereotactic radiation for pancreatic and hepatobiliary tumours — our specialist set up the pioneering NCCS programmes.
Intensity-modulated delivery keeps stomach, bowel and kidney dose low across every abdominal course.
Chemotherapy and targeted therapy planned alongside radiation in one multidisciplinary pathway.
Every plan at AARO goes through detailed contouring, dose simulation, and independent physics review before a single beam is delivered. We do this so the radiation hits exactly the tissue that needs it — and avoids the healthy tissue around it.
Our medical physicists and radiation therapists collaborate on each plan — contouring tumour and organs-at-risk, simulating dose distribution, and independently checking every parameter before delivery.
Imaging before each fraction confirms the target's position to the millimetre — so tight margins stay safe, and healthy tissue stays out of the high-dose region.
Each treatment session takes 15–30 minutes. You'll lie on a precision treatment couch beneath the linear accelerator. Positioning lasers and daily imaging align you to within a millimetre of the planned position.
You won't feel the radiation as it's delivered. There's no anaesthesia, no recovery time, and no overnight stay. Most patients drive themselves home after the session and return to normal activities the same day.
GI radiation at AARO is led by sub-specialists in upper GI, hepatobiliary and colorectal cancers, with internationally published chemoradiation expertise.
Book a 45–60 minute specialist consultation. We'll review your imaging and pathology, explain the options that apply to your case, and answer your questions.